Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver first-in-class transformative therapies for patients facing life-changing disease, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company’s Multabody™ platform, a novel approach to stimulating key targets in immunotherapy that have remained out of reach due to toxicity or lack of response.
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform
Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has closed a $35 million Series A financing. The round is co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures of Canada.
Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV
Radiant Biotherapeutics, a startup biotechnology company developing a revolutionary antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has received a USD $2 million grant from the Bill & Melinda Gates Foundation to develop the next generation of HIV biologics based on Radiant’s Multabody™ platform.
Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma PartnershipsBreakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications
